

An Overview: Hepatitis C Online and Hepatitis B Online

Julia Freimund
Program Manager
Infectious Diseases Education & Assessment (IDEA) Program
juliasf@uw.edu

No disclosures

January 20, 2022

Overview

Sections on Hepatitis C Online and Hepatitis B Online

- Lessons (Self-Study and Quick Reference)
- Medications
- Tools & Calculators
- Clinical Challenges
- Learning Groups
- Unique sections to each site

Overview

Hepatitis C Online

- HCV Biology

Hepatitis B Online

- Hepatitis B Management: Guidance for the Primary Care Provider
- HBV Vaccines
- HBV Mini-Lectures

Both curriculums are funded through a Centers for Disease Control and Prevention (CDC) Cooperative Agreement (CDC-RFA-PS21-2105) and developed by the University of Washington Infectious Diseases Education & Assessment (IDEA) Program.

HCV
BiologyHCV
MedicationsCourse
ModulesTools &
CalculatorsClinical
ConsultationClinical
ChallengesMaster
Bibliography

Hepatitis C Online

A free educational website from the
University of Washington Infectious Diseases Education & Assessment (IDEA) program

[Contributors](#)

Funded by
Centers for Disease Control and Prevention (CDC)

HCV Medications

[Medication Summaries](#)[Prescribing Information](#)[Clinical Studies](#)[Slide Decks](#)[Learn about medications to treat HCV »](#)

HCV Course Modules

Screening and Diagnosis of Hepatitis C Infection

For any clinician who may encounter persons with hepatitis C virus infection and would like to establish core competence in testing for hepatitis C, counseling patients on preventing hepatitis C transmission, and diagnosing acute hepatitis C infection.

[Overview / Quick Reference](#) >

Rapidly access info about Screening and Diagnosis of Hepatitis C Infection

[Clinical Challenges](#)

Expert opinions for challenging and controversial cases

[Self-Study](#) **3rd Edition** **CNE/CME**

Track your progress and receive CE credit

Evaluation, Staging, and Monitoring of Chronic Hepatitis C

[Overview / Quick Reference](#) >

Rapidly access info about Evaluation, Staging, and Monitoring of Chronic Hepatitis C

[Clinical Challenges](#)

Expert opinions for challenging and controversial cases

Learning Portal and Information Resource

Hepatitis C Online

Course
Modules

6 Modules
34 Lessons

HCV
Medications

7
Medications

Tools and
Calculators

12
Tools/
Calculators

Clinical
Challenges

New in 2022

HCV Biology

Structure
Proteins
Life Cycle

34 Free CME/CNE/CE
18 Pharmacology CE for APNs
& Certificates of Completion

6 Modules: 34 Lessons


Recertified for CE (3rd Edition) in Spring 2021, six modules with 34 lessons address:

- Screening and Diagnosis
- Evaluation, Staging, and Monitoring of Chronic Hepatitis C Management
- Management of Cirrhosis-Related Complications
- Evaluation and Preparation for Hepatitis C Treatment
- Treatment of Chronic Hepatitis C Infection
- Treatment of Key Populations and Unique Situations

34 free CME credit, CNE contact hours, and CE contact hours: 18 pharmacology CE for advanced practice nurses; and Certificates of Completion are also available

Lessons

Dual Functionality



Self-Study Lessons

- Sequential or flexible
- Earn CME/CNE/CE
- Earn Certificates of Completion
- Sign in required
- Ideal for courses & trainings

Registered Learners

Quick Reference Lessons

- Highly organized interface
- Quick search
- On demand topics
- No sign in required
- Ideal for staying updated

All Learners



HCV
Biology



HCV
Medications



Course
Modules



Tools &
Calculators



Clinical
Consultation



Clinical
Challenges



Master
Bibliography



1 Screening and Diagnosis of Hepatitis C Infection

Self-Study



HCV Epidemiology in
the United States

Recommendations for
Hepatitis C Screening

Hepatitis C
Diagnostic
Testing

Counseling for Prevention
of HCV Transmission

Diagnosis of Acute
HCV Infection



Certificate of Completion

Screening and Diagnosis of Hepatitis C Infection

You are just a few steps away from free CE credits!

1 ★

Sign in or Register

A free account is required.

2

Study the Material

An entire module, or just a few topics at a time.

3

Take the CE Quiz

5 questions covering the topics in each module.

4

Claim CE Credit

Free CNE and Free CME available!

New Users

Create a free account to get started.

Required for CE

Register >

Returning Users



Email Address

Password

Forgot password?

Sign in >

1 Screening and Diagnosis of Hepatitis C Infection

Self-Study

HCV Epidemiology in the United States

Recommendations for Hepatitis C Screening

Hepatitis C Diagnostic Testing

Counseling for Prevention of HCV Transmission

Diagnosis of Acute HCV Infection

Certificate of Completion

Lesson 2. Recommendations for Hepatitis C Screening - 17% complete
Topic 1. Current Hepatitis C Testing Recommendations

Topic 1. Current Hepatitis C Testing Recommendations

← Back

Next: Lesson 2 Topic 2 →

CURRENT HEPATITIS C TESTING RECOMMENDATIONS

Recently, several organizations have issued hepatitis C virus (HCV) screening recommendations. In general, major guidelines now recommend routine one-time universal HCV testing for adults 18 years of age and older, routine HCV screening of pregnant individuals, screening younger persons at risk of acquiring HCV, and repeat screening for those with ongoing risk for HCV acquisition.

2020 CDC RECOMMENDATIONS FOR HCV SCREENING

On April 10, 2020, the Centers for Disease Control and Prevention (CDC) issued new recommendations for hepatitis C screening among adults in the United States (Table 1).

[1] This new guidance augments prior CDC guidance on HCV screening with two new major recommendations: (1) all adults aged 18 years and older should have HCV screening at least once in their lifetime, except in settings where the prevalence of HCV infection is less than 0.1%, and (2) HCV screening should be performed for all pregnant persons during each pregnancy, except in settings where the prevalence of HCV infection is less than 0.1%. [1] The CDC continues to recommend screening persons for HCV regardless of age if risk factors for acquiring HCV are present, with repeat periodic screening in persons who have ongoing risk for acquiring HCV. These new CDC HCV screening recommendations expand prior guidance that recommended routine HCV screening for all persons born between 1945-1965. [1,2,3]

2020 USPSTF HCV SCREENING RECOMMENDATIONS

In March 2020, the U.S. Preventive Services Task Force (USPSTF) issued updated recommendations regarding screening for HCV. The USPSTF now recommends routine screening for all adults in the United States 18-79 years of age, including pregnant women (USPSTF Screening for Hepatitis C Infection [4,5,6]). The 2020 USPSTF recommendation for HCV screening was categorized as a grade B recommendation, which means that the USPSTF concludes with moderate certainty that screening for HCV in adults 18-79 years of age has a net benefit. [4,5,6] The USPSTF also states that the net benefit of screening for HCV in adults 18-79 years of age is moderate to high.

Table 1. CDC Recommendations for Hepatitis C Screening Among Adults — United States

Topic
CDC Recommendations for Hepatitis C Screening Among Adults — United States
Persons Recommended for Screening
Universal Hepatitis C Screening
• Hepatitis C screening of all adults aged 18 years and older in a clinical or community setting where the prevalence of HCV infection is less than 0.1%.
• Hepatitis C screening for all pregnant persons during each pregnancy, except in settings where the prevalence of HCV infection is less than 0.1%.
Universal Hepatitis C Testing regardless of age or testing prevalence among persons with recognized risk factors or exposures
• Persons with HIV
• Persons who use injection drugs and shared needles, syringes, or other drug preparation equipment, including those who reported use of a first-time-use only (FTU) syringe
• Persons with selected medical conditions, including persons who have received transfusions, hemodialysis, and persons with previously abnormal albumin-to-creatinine (A/C) ratios
• All risk categories of blood or blood components before July 1993, persons who received an organ transplant before July 1993, and persons who were notified of their transfusion history or donor who also reported exposure to HIV infection
• Health care emergency medical and dental safety personnel after needle sticks, sharps, or mucous exposures to HCV-positive blood
• Children born to mothers with HIV infection
Positive periodic testing for persons with ongoing risk factors, unless risk factors persist
• Persons who currently inject drugs and share needles, syringes, or other drug preparation equipment
• Persons who obtained medical equipment, including syringes who also have reported exposure to HIV infection

Table 1. CDC Recommendations for Hepatitis C Screening Among Adults — United States

Overview

Next: Lesson 3 Topic 1 >

Your Progress

About the Module

Certificate Requirements

Core Competencies

Treatment of Key Populations and Unique Situations Progress Tracker - 3rd Edition

Certificate of Completion »

CNE Certificate »

	<i>Lesson 1</i> Treatment of Acute HCV Infection	<i>Lesson 2</i> Treatment of HCV in Persons with HIV Coinfection	<i>Lesson 3</i> Treatment of HCV in Persons with Renal Impairment	<i>Lesson 4</i> Treatment of HCV in Persons with Cirrhosis	<i>Lesson 5</i> Treatment of HCV in Persons with Substance Use	<i>Lesson 6</i> Treatment of HCV in a Correctional Setting	<i>Lesson 7</i> Management of Health Care Personnel Exposed to HCV	<i>Lesson 8</i> Perinatal HCV Transmission
Topic 1	✓	✓					✓	✓
Topic 2	✓	✓					✓	✓
Topic 3	✓	✓					✓	✓
Topic 4	✓	✓					✓	✓
Topic 5	✓	✓					✓	✓
Topic 6	✓	✓					✓	✓
Topic 7								✓
Topic 8								✓
Topic 9								✓
Topic 10								✓
Lesson Quiz	🎯 CNE ✓	🎯 CNE ✓					🎯 CNE ✓	🎯 CNE ✓

Registered Learners

Quick Reference Lessons



HCV
Biology



HCV
Medications >



Course
Modules ▾



Tools &
Calculators >



Clinical
Consultation

View all Course Modules

1 Screening and Diagnosis
of Hepatitis C Infection >

2 Evaluation, Staging, and
Monitoring of Chronic
Hepatitis C >

3 Management of Cirrhosis-
Related Complications >

4 Evaluation and
Preparation for Hepatitis
C Treatment >

5 Treatment of Chronic
Hepatitis C Infection >

6 Treatment of Key
Populations and Unique
Situations >

Quick Reference **3rd Edition**

Rapidly access information in this module



**Screening and Diagnosis of Hepatitis C Infection:
Overview**

LESSONS

1. HCV Epidemiology in the United States
2. Recommendations for Hepatitis C Screening
3. Hepatitis C Diagnostic Testing
4. Counseling for Prevention of HCV Transmission
5. Diagnosis of Acute HCV Infection

All Visitors/Learners



Screening and Diagnosis of Hepatitis C Infection
Recommendations for Hepatitis C Screening



Recommendations for Hepatitis C Screening

CME/CNE Earn CE credit for this module

Last Updated: May 26th, 2021

Author: David H. Spach, MD

Reviewer: Maria A. Corcorran, MD, MPH

CURRENT HEPATITIS C TESTING RECOMMENDATIONS

Recently, several organizations have issued hepatitis C virus (HCV) screening recommendations. In general, major guidelines now recommend routine one-time universal HCV testing for adults 18 years of age and older, routine HCV screening of pregnant individuals, screening younger persons at risk of acquiring HCV, and repeat screening for those with ongoing risk for HCV acquisition.

2020 CDC RECOMMENDATIONS FOR HCV SCREENING

On April 10, 2020, the Centers for Disease Control and Prevention (CDC) issued new recommendations for hepatitis C screening among adults in the United States (Table 1).^[1] This new guidance augments prior CDC guidance on HCV screening with two new major recommendations: (1) all adults aged 18 years and older should have HCV screening at least once in their lifetime, except in settings where the prevalence of HCV infection is less than 0.1%, and (2) HCV screening should be performed for all pregnant persons during each pregnancy, except in settings where the prevalence of HCV infection is less than 0.1%.^[1] The CDC continues to recommend screening persons for HCV regardless of age if risk factors for acquiring HCV are present, with repeat periodic screening in persons who have ongoing risk for acquiring HCV. These new CDC HCV screening recommendations expand prior guidance that recommended routine HCV screening for all persons born between 1945-1965.^[1,2,3]

2020 USPSTF HCV SCREENING RECOMMENDATIONS

In March 2020, the U.S. Preventive Services Task Force (USPSTF) issued updated recommendations regarding screening for HCV. The USPSTF now recommends routine screening for all adults in the United States 18-79 years of age, including pregnant women (USPSTF Screening for

Table 1. CDC Recommendations for Hepatitis C Screening Among Adults — United States
Universal Hepatitis C Screening
• Hepatitis C screening at least once in a lifetime for all adults aged ≥ 18 years, except in settings where the prevalence of HCV infection (HCV) has been estimated to be < 0.1%.
• Hepatitis C screening for all pregnant women during each pregnancy, except in settings where the prevalence of HCV infection (HCV) has been estimated to be < 0.1%.
Diagnostic Hepatitis C Testing (regardless of age or testing prevalence among persons with recognized risk factors or exposures)
• Persons with risk
• Persons who have reported drug and shared needles, syringes, or other drug preparation equipment, including those who injected drugs or a few times many years ago
• Persons with selected medical conditions, including persons who ever received transfusions, hemodialysis, and persons who previously donated plasma or other transfusable blood products
• Persons who received transfusions or organ transplants, including persons who received clotting factor concentrates produced before 1987, persons who received a transfusion of blood or blood components before July 1993, persons who received an organ transplant before July 1992, and persons who were notified that they received blood from a donor who later tested positive for HCV infection
• Health care, emergency medical, and public safety personnel after needle sticks, sharps, or mucous exposures to HCV-positive blood
• Children born to mothers with HCV infection
Repeat periodic testing for persons with ongoing risk factors, while risk factors persist
• Persons who currently inject drugs and share needles, syringes, or other drug preparation equipment
• Persons with selected medical conditions, including persons who ever received transfusions, hemodialysis
Any person who requests hepatitis C testing should receive it, regardless of disclosure of risk, because every person might be reluctant to disclose risk-taking behaviors

Table 1. CDC Recommendations for Hepatitis C Screening Among Adults — United States

HCV Medications



HCV Medications

Prescribing Information, Clinical Studies, and Slide Decks

All materials are available for download in their original formats as PDF or PowerPoint.

Section Editors

David H. Spach, MD, H. Nina Kim, MD

FDA-Approved

Elbasvir-Grazoprevir

Zepatier

Summary »

Prescribing Information »

Clinical Trials »

References »



Glecaprevir-Pibrentasvir

Mavyret

Summary »

Prescribing Information »

Clinical Trials »

References »



Ledipasvir-Sofosbuvir

Harvoni

Summary »

Prescribing Information »

Clinical Trials »

References »



Ribavirin

Copegus, Rebetol, Ribasphere

Summary »

Prescribing Information »

Clinical Trials »

References »



Sofosbuvir

Sovaldi

Summary »

Prescribing Information »

Clinical Trials »

References »



Sofosbuvir-Velpatasvir

Epclusa

Summary »

Prescribing Information »

Clinical Trials »

References »



Sofosbuvir-Velpatasvir-Voxilaprevir

Vosevi

Summary »


Prescribing Information »

Clinical Trials »

References »



All Visitors/Learners



Elbasvir-Grazoprevir (Zepatier)

Other Names: EBR-GZR

- Editor's Summary
- Prescribing Information**
- Clinical Trials
- References
- Slide Deck
- Teaching Resources

Prescribing information last updated May 25, 2022 (provided by Merck Sharp & Dohme LLC).

↓ Fetched from DailyMed [↗](#) on June 21, 2022.

BOXED WARNING

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with ZEPATIER. HBV reactivation has been reported in HCV/HBV coinfecting patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfecting patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see *Warnings and Precautions* (5.1)].

RECENT MAJOR CHANGES







Indications and Usage (1)	12/2021
Dosage and Administration, Recommended Dosage in Adult and Pediatric Patients 12 Years of Age and Older or Weighing at Least 30 kg (2.2)	12/2021

1. INDICATIONS AND USAGE

Elbasvir-Grazoprevir Zepatier

Tablet Prescribing Information

- Boxed Warning
- Recent Major Changes
- 1. Indications and Usage
- 2. Dosage and Administration
- 3. Dosage Forms and Strengths
- 4. Contraindications
- 5. Warnings and Precautions
- 6. Adverse Reactions
- 7. Drug Interactions
- 8. Use in Specific Populations
- 10. Overdosage
- 11. Description
- 12. Clinical Pharmacology
- 13. Nonclinical Toxicology
- 14. Clinical Studies
- 16. How Supplied/Storage and Handling
- 17. Patient Counseling Information
- Spl Unclassified Section
- Patient Package Insert
- Spl Unclassified Section
- Package Label, Principal Display Panel



Elbasvir-Grazoprevir (Zepatier)

Other Names: **EBR-GZR**

[Editor's Summary](#)[Prescribing Information](#)[Clinical Trials](#)[References](#)[Slide Deck](#)[Teaching Resources](#)

Editor's Summary



A PDF version of this treatment drug's summary, including the clinical trial descriptions and references.

Elbasvir-Grazoprevir Slide Deck



March 30, 2022

Clinical Trial Image Decks



C-EDGE CO-STAR - April 1, 2022



C-EDGE Coinfection - March 30, 2022



C-EDGE Treatment-Experienced - March 30, 2022



C-EDGE Treatment-Naïve - March 30, 2022

Clinical Calculators

12 Clinical Calculators & Screening Tools

Using your own electronic device, you can access:

Clinical Calculators	
CTP Calculator	Substance Use Screening Tools
APRI Calculator	
BMI Calculator	
CrCl Calculator	Alcohol: AUDIT-C
FIB-4 Calculator	Alcohol: CAGE
Glasgow Coma Scale	Opioid: Risk Tool
GFR Calculator	
MELD Calculator	
SAAG Calculator	

All Visitors/Learners

Clinical Challenges

Challenges and Controversies

Expert Opinions for Challenging and Controversial Cases

Opinions submitted by experts from across the nation.

Section Editors

[Maria A. Corcoran, MD, MPH](#)

Available Topics

Recently Added >

Evaluation, Staging, and Monitoring of Chronic Hepatitis C ▾

[Evaluation and Staging of Liver Fibrosis \(1 case\)](#)

[Treatment of Chronic Hepatitis C Infection](#) >

[Treatment of Key Populations and Unique Situations](#) >

Addressing discordant fibrosis staging

May 24, 2022

Clinical Challenge

A 62-year-old woman is seen for follow-up to consider treatment of genotype 3 hepatitis C virus (HCV). She was diagnosed with HCV 20 years ago but has never been treated. Her laboratory evaluation reveals the following: HCV RNA level 657,912 IU/mL, AST 45 U/L, ALT 92 U/L, total bilirubin 1.0 mg/dL, platelets 155,000/mm³. You calculate her AST to Platelet Ratio Index (APRI) to be 0.7, but her FibroSure result return showing F4 fibrosis.

Would you perform any additional fibrosis staging before treatment?

- No, I would proceed directly to treatment.
- Yes, I would perform a FibroScan to better ascertain her level of fibrosis before treatment.
- Yes, I would perform a liver biopsy to better ascertain her level of fibrosis before treatment.
- Another option not listed above.

[View Expert Opinions](#)

[View Member Responses](#)

Submit >



Expert Opinions

[Karla Thornton, MD, MPH](#)

All Visitors/Learners

Learning Groups

Why Online Learning Groups are Formed

- Train or onboard staff and residents by assigning selected topics
- Review group progress to track work, completions, and CE
- Implement a training plan across multiple locations
- Augment medical, nursing, pharmacy, dental and other healthcare professionals training programs

First Step to Form a Learning Group

The screenshot shows a user profile for Julia Freimund, an IDEA Program Manager. The profile menu includes options for account settings, CNE/CME CE profile, and Progress Tracker. The 'Learning Groups' section is highlighted with a red box and contains the following options:

- Join or Create a Group »
- My Groups »


Below the 'Learning Groups' section, two groups are listed:

- Hepatitis 101** (Owner):
 - Modify group »
 - Manage members »
 - View group's progress »
- Hepatitis C Demo Group** (Learner)


At the bottom of the menu is a 'Sign out »' option.

Learning Groups: Invite, Organize, & Track

Group Leader



Invite,
Organize
& Track



Home Progress Analytics Members Settings






Only current learners' progress is included. Use the tabs below to look at progress within the individual parts of the curriculum.

Active Learners (last 30 days) **0** **Current Learners** **11**

Course Modules

View progress for: Screening and Diagnosis of Hepatitis C Infection (3rd Ed.)

50 records per page Search:

Learners	HCV Epidemiology in the United States	Recommendations for Hepatitis C Screening	Hepatitis C Diagnostic Testing	Counseling for Prevention of HCV Transmission	Diagnosing HCV Infection
 [redacted]	80%	100%	Hepatitis C Diagnostic Testing	80%	100%
 [redacted]	100%	100%	Progress: 100% Accessed: January 22, 2022, 12:47 pm	80%	100%
 [redacted]	100%	80%	Attempt 1: CNE 4/5 - 80%	100%	100%
 [redacted]	100%	100%	80%	100%	100%
 [redacted]	80%	100%	80%	100%	100%

HCV Biology

Explore HCV Biology at
www.hepatitisc.uw.edu

Hepatitis C Online's newest section, **Hepatitis C Virus Biology**, explores basic concepts related to the biology of hepatitis C virus (HCV). Knowledge of the HCV structure and life cycle, including how genetic material from the virus is turned into structural and non-structural proteins, is key in understanding the mechanism of the direct-acting antivirals (DAAs) used to treat HCV. This innovative new section offers:


- High-resolution conceptual illustrations
- Clear, concise information about the structure, proteins, and life cycle
- Comprehensive references

Hepatitis C Online is a **free, comprehensive educational resource** for diagnosing, monitoring, and managing HCV. The website features 33 lessons across 6 modules, an in-depth medications section, and 11 clinical calculators and tools.


Free CME credits, CNE contact hours, and pharmacology CE for advanced practice nurses.

HCV BIOLOGY EXAMPLES


LIPOVIRAL PARTICLE




FUSION & UNCOATING




RNA REPLICATION



1. HCV STRUCTURE




2. HCV PROTEINS



1. Examine the different structural elements of the HCV virus.
2. Discover details on the structure and function for all ten HCV proteins.

3. HCV LIFE CYCLE



3. Navigate through the nine phases (from binding to release) with a tour of detailed images and concise descriptions about each major step in the HCV life cycle.

Funded through a Centers for Disease Control and Prevention Cooperative Agreement (CDC-RFA-PS16-1608) and developed by the National Hepatitis Training Center at the University of Washington (UW) and the UW Infectious Diseases Education and Assessment (IDEA) team.

Hepatitis B Online

[Quick Reference](#) >[Self Study](#) >[Hepatitis B Primary Care Guidance](#)[HBV Medications](#) >[Clinical Challenges](#)[Tools & Calculators](#) >[Mini-Lectures](#)

Hepatitis B Online

A free educational website from the University of Washington Infectious Diseases Education & Assessment (IDEA) program

[Contributors](#)

Funded by
Centers for Disease Control and Prevention (CDC)

HBV Medications

[Prescribing Information](#)
[Clinical Studies](#)
[Slide Decks](#)

[Learn about medications to treat HBV »](#)



Hepatitis B Online Lessons

HBV Epidemiology

Reviews United States and global HBV incidence and prevalence, populations at risk for HBV acquisition, and the clinical and laboratory criteria for HBV case definitions.

[Quick Reference](#) >

Rapidly access info about HBV Epidemiology

[Self-Study](#) **2nd Edition** **CNE/CME**

Track progress and receive CE credit

HBV Screening and Diagnosis

Details the groups considered at priority for HBV testing, the recommended screening and diagnostic tests, and how to interpret HBV diagnostic test results.

[Quick Reference](#) >


Rapidly access info about Screening and Diagnosis

[Self-Study](#) **CNE/CME**

Track progress and receive CE credit

Learning Portal and Information Resource

Hepatitis B Online



Hepatitis B Online: Summary of CME Credit, CNE Contact Hours, CE Contact Hours, and Pharmacology CE for Advanced Practice Nurses as of 1/17/23

Hepatitis B Online Lesson	Lesson	CME/CNE/CE	Pharmacology CE for APNs
HBV Epidemiology	1	1.00	0.00
HBV Screening and Diagnosis *	2	1.00	0.00
HBV Immunizations	3	1.50	1.50
Initial Evaluations of Persons with Chronic Hepatitis B *	4	1.00	0.00
When to Initiate HBV Treatment	5	1.00	1.00
Choosing an Initial HBV Treatment Regimen	6	1.00	1.00
Preventing HBV Perinatal Transmission	7	1.50	1.50
Screening for Hepatocellular Carcinoma	8	1.00	0.00
Occupational HBV Postexposure Prophylaxis	9	1.00	1.00
Hepatitis B Reactivation in the Setting of Immunosuppression	10	1.00	1.00
Combined total for Lessons as of 1/17/23		11.00	7.00
11 CME/CNE/CE and 7 Pharmacology CE		CME/CNE/CE	Pharm CE

* - 2nd Edition of this lesson will launch in 2/23

Oral Antivirals (Nucleos(t)ide Analogues)

Adefovir

Hepsera

- [Prescribing Information »](#)
- [Clinical Trials »](#)
- [References »](#)

Entecavir

Baraclude

- [Prescribing Information »](#)
- [Clinical Trials »](#)
- [References »](#)
- [Slide Deck »](#)

Lamivudine

Epivir HBV

- [Prescribing Information »](#)
- [Clinical Trials »](#)
- [References »](#)
- [Slide Deck »](#)

Tenofovir alafenamide

Vemlidy

- [Prescribing Information »](#)
- [Clinical Trials »](#)
- [References »](#)
- [Slide Deck »](#)

Tenofovir DF

Viread

- [Prescribing Information »](#)
- [Clinical Trials »](#)
- [References »](#)
- [Slide Deck »](#)

Immune Modulators (Interferons)

Interferon alfa-2b

Intron A

- [Prescribing Information »](#)
- [Clinical Trials »](#)

Peginterferon alfa-2a

Pegasys

- [Prescribing Information »](#)
- [Clinical Trials »](#)

Vaccines (HBV)

Engerix-B

Engerix-B

[Prescribing Information »](#)

[Clinical Trials »](#)

[References »](#)

Heplisav-B

Heplisav-B

[Prescribing Information »](#)

[Clinical Trials »](#)

[References »](#)

[Slide Deck »](#)

PreHevbrio

PreHevbrio

[Prescribing Information »](#)

[Clinical Trials »](#)

[References »](#)

[Slide Deck »](#)

Recombivax-HB

Recombivax-HB

[Prescribing Information »](#)

[Clinical Trials »](#)

[References »](#)

Twinrix

Twinrix

[Prescribing Information »](#)

[Clinical Trials »](#)

[References »](#)

All Visitors/Learners



Quick Reference >



Self Study >



Hepatitis B Primary Care Guidance



HBV Medications >



Clinical Challenges



Tools & Calculators >




Mini-Lectures

National Hepatitis B Curriculum Mini-Lectures

Experts discuss clinically relevant topics in concise lectures. New content will be added throughout the year. CE is not available.

No permission is required when distributing or adapting the images, figures, tables, and content for noncommercial purposes. For permission, please [contact us](#).

Subscribe to these mini-lectures on our  **YouTube Channel @HBV_online!**

Core Antibody



Anti-HBc

Icterus Virus

Core

Envelope

Image Credit: Cognition-Media, Inc.

Medicine 360

Isolated Hepatitis B Core Antibody (13:32)

WATCH OCTOBER 21, 2022

Virologic and Serologic Response to Acute HBV Infection with Recovery



Symptoms

■ HBV DNA
■ HBsAg
■ HBeAg
■ Total anti-HBc
■ IgM anti-HBc
■ Anti-HBc
■ Anti-HBe

Time

Weekly Mean Exposure

0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60

0 10 20 30 40 50 60 70 80 90 100

Duration Credit: Peter H. Rasmussen, MD

Medicine 360

Interpreting Hepatitis B Serologies (7:26)

WATCH OCTOBER 21, 2022

Hepatitis B Management: Guidance for the Primary Care Provider

Developed by the Hepatitis B Primary Care Workgroup and produced in collaboration with the University of Washington Infectious Diseases Education & Assessment (IDEA) program.

 [Download as PDF - 125KB](#)

Tip: when using *Reader View* below, use navigation tools on the side (*Page Flip*) and below (*Scroll, Zoom, Find, and Fullscreen*).

[or view it below](#)

The purpose of this document is to provide simplified, up-to-date, and readily accessible guidance for primary care medical providers related to the prevention, diagnosis, and management of hepatitis B virus (HBV) infection, including hepatocellular carcinoma surveillance.

About the HBV Primary Care Workgroup


This guidance was developed by the Hepatitis B Primary Care Workgroup, a multidisciplinary panel of national experts in the field of viral hepatitis B, including representation from hepatology, infectious diseases, pharmacy, primary care, public health, and other national organizations. The workgroup was organized by the National Taskforce on Hepatitis B in partnership with the San Francisco Hep B Free — Bay Area and Project ECHO™ and did not receive any outside funding.

Hepatitis B Management: Guidance for the Primary Care Provider

TABLE OF CONTENTS

■ Chronic Hepatitis B Testing and Management Algorithm	2
■ Hepatitis B Virus (HBV) Serology Interpretation and Management.....	3
■ Initial Evaluation of the HBsAg(+) Patient	4
■ Counseling of the HBsAg(+) Patient.....	4
■ Management of the HBsAg(+) Patient	5
■ Preferred Antiviral Treatment of the HBsAg(+) Patient	6
■ Hepatocellular Carcinoma (HCC) Surveillance.....	7
■ Perinatal HBV Management	8
■ Selected References	9
■ HBV Primary Care Workgroup Members	10
■ Disclosures	11

Chronic Hepatitis B Testing and Management Algorithm



¹ Do not include anti-HBc IgM in HBV screening panel unless suspect acute HBV.

Promotional Material



FREE CE Offered

IDEA Curricula	CME Credits/MOC Points CNE Contact Hours CE Contact Hours	Pharmacology CE for Advanced Practice Nurses
National HIV Curriculum hiv.uw.edu	97.50 97.50 Maintenance of Certification (MOC) Points	70.50
National STD Curriculum std.uw.edu	30.50 30.50 MOC	14.25
Hepatitis C Online hepatitisC.uw.edu	34.00	18.00
Hepatitis B Online hepatitisB.uw.edu	11.00	7.00



HEPATITIS B ONLINE

www.hepatitisB.uw.edu



HEPATITIS C ONLINE

www.hepatitisC.uw.edu

Free CME, CNE, Pharmacology CE, and CE


TWO FREE, up-to-date websites on how to diagnose, treat, and prevent hepatitis B and hepatitis C virus infection

Healthcare professionals and trainees visit these sites to:

- Access **self-study lessons**, earn free CE, and track progress
- Search for current information or scan through the **quick reference** section
- Use 11 clinical screening **tools and calculators** to help with clinical decisions
- Review **medications**, examine clinical trials, and view/download slide decks
- Explore **clinical challenges** and learn how experts approach these scenarios
- Create a free **online learning group** to assign students or staff lessons, then track their progress or CE

Funded through a Centers for Disease Control and Prevention Cooperative Agreement (CDC-RFA-PS21-2105). University of Washington (UW) Professor of Medicine Dr. David Spach is Editor-in-Chief of these sites, the National HIV Curriculum, and the National STD Curriculum. Developed by the UW Infectious Diseases Education & Assessment (IDEA) Program (idea.medicine.uw.edu).

THE UNIQUE FEATURES OF THESE SITES ALLOW VISITORS TO:



HEPATITIS B ONLINE
 Quick Reference | Self Study | **Hepatitis B Primary Care Guidance** | HBV Medications | HBV Vaccines | Clinical Challenges | Tools & Calculators

Hepatitis B Management: Guidance for the Primary Care Provider

Developed by the Hepatitis B Primary Care Workgroup and produced in collaboration with the University of Washington Infectious Diseases Education & Assessment (IDEA) program.


[Download as PDF - 1.25KB](#)

or view it below

Tip: when using Reader View below, use navigation tools on the side (Page F1/s) and below (Scroll, Zoom, Find, and Fullscreen).

- Review five Hepatitis B Vaccines
- View or download a **simplified guidance** to diagnose, manage, and prevent HBV

- Explore high-quality illustrations and descriptions of HCV structure, proteins, and life cycle




HEPATITIS C ONLINE
 HCV Biology | HCV Medications | Course Modules | Tools & Calculators | Clinical Consultation | Clinical Challenges | Master Bibliography

Hepatitis C Virus Biology




HCV STRUCTURE >



HCV PROTEINS >



HCV LIFE CYCLE >



Funded by
Centers for Disease Control and Prevention (CDC)

Course Modules

Access to Quick Reference Information
Track progress with Self-Study Modules
Free CME credits and CNE/CE contact hours

Start the Self-Study Modules >



HEPATITIS C ONLINE

- ➔ **FREE**, up-to-date comprehensive educational resource for diagnosing, monitoring, and managing hepatitis C virus infection (HCV)
- ➔ **FREE** CME credits and CNE contact hours for 34 lessons, pharmacology CE for advanced practice nurses, and CE contact hours available
- ➔ **Self-study** or **quick reference modules** on the following topics:
 - Screening and Diagnosis of Hepatitis C Infection
 - Evaluation, Staging, and Monitoring of Chronic Hepatitis C
 - Management of Cirrhosis-Related Complications
 - Evaluation and Preparation for Hepatitis C Treatment
 - Treatment of Chronic Hepatitis C Infection
 - Treatment of Key Populations and Unique Situations
- ➔ **HCV Biology** section features high-quality illustrations and detailed descriptions of HCV structure, HCV proteins, and the multiple steps in the HCV life cycle
- ➔ Eleven **clinical calculators** or tools provide clinical decision support
- ➔ **HCV Medications** section that includes in-depth information on direct-acting antiviral medications, including prescribing info, clinical studies, and slide decks
- ➔ Interactive **Clinical Challenges** provide treatment options and expert opinions
- ➔ Innovative group learning tool to assign units and track members' progress
- ➔ Funded through a Centers for Disease Control and Prevention Cooperative Agreement (CDC-RFA-PS21-2105) and developed by the University of Washington (UW) Infectious Diseases Education and Assessment (IDEA) Program
- ➔ UW Professor of Medicine Dr. David Spach is Editor-in-Chief of this site, the CDC-funded Hepatitis B Online (www.hepatitisB.uw.edu), the CDC-funded National STD Curriculum (www.std.uw.edu), and the HRSA-funded National HIV Curriculum (www.hiv.uw.edu).

Hepatitis C Online (www.hepatitisC.uw.edu)

Hepatitis B Online

A free educational website from the University of Washington Infectious Diseases Education & Assessment (IDEA) program

Contributors

Funded by
Centers for Disease Control and Prevention (CDC)

HBV Primary Care Guidance

From the HBV Primary Care Workgroup
Practical Guidance for Clinicians
View Online or Download

View the Guidance >



HEPATITIS B ONLINE

- ➔ **FREE**, up-to-date educational resource for diagnosing, monitoring, managing, and preventing hepatitis B virus infection (HBV)
- ➔ **Self-study lessons** offer **FREE** CME credits, CNE contact hours, pharmacology CE for advanced practice nurses, and CE contact hours available
- ➔ **Hepatitis B Management: Guidance for the Primary Care Provider**, simplified and current, was developed by a multidisciplinary panel of national experts
- ➔ Eleven **clinical calculators** or tools provide clinical decision support
- ➔ **HBV Medications and Vaccinations** section include in-depth information on prescribing, clinical studies, and slide decks
- ➔ Interactive **Clinical Challenges** provide treatment options and expert opinions
- ➔ Experts discuss clinically relevant topics in **Mini-Lectures** section
- ➔ Innovative **group learning** tool to assign units and track members' progress – a popular feature used by healthcare organizations and training programs
- ➔ Funded through a Centers for Disease Control and Prevention Cooperative Agreement (CDC-RFA-PS21-2105), Hepatitis B Online is managed by the University of Washington (UW) Infectious Diseases Education and Assessment (IDEA) program
- ➔ UW Professor of Medicine Dr. David Spach is Editor-in-Chief of this site, the CDC-funded Hepatitis C Online (www.hepatitisC.uw.edu), the CDC-funded National STD Curriculum (www.std.uw.edu), and the HRSA-funded National HIV Curriculum (www.hiv.uw.edu).

Hepatitis B Online (www.hepatitisB.uw.edu)

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



The contents in this presentation are those of the author(s) and do not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.